@article{fdi:010075674,
  title = {{C}hronic kidney disease and {HIV} in the era of antiretroviral treatment : findings from a 10-year cohort study in a west {A}frican setting},
  author = {{K}abor{\'e}, {N}. {F}. and {P}oda, {A}. and {Z}oungrana, {J}. and {D}a, {O}. and {C}iaffi, {L}. and {S}emd{\'e}, {A}. and {Y}ameogo, {I}. and {S}awadogo, {A}. {B}. and {D}elaporte, {E}. and {M}eda, {N}. and {L}imou, {S}. and {C}ournil, {A}mandine},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground{I}t has been reported that people living with {HIV} in {W}est {A}frica exhibited the highest risks for chronic kidney disease ({CKD}) in the world. {H}ere, we aimed at determining the {CKD} frequency and changes in kidney function during antiretroviral treatment ({ART}) in a large cohort of {HIV}-patients followed in {B}urkina {F}aso.{M}ethods{W}e included {ART}-naive adults who initiated {ART} at the {D}ay {C}are {U}nit of the {S}ouro {S}anou {U}niversity {H}ospital between 01/01/2007 and 12/31/2016. {W}e assessed the estimated glomerular filtration rate (e{GFR}) by serum creatinine using the {M}odification of {D}iet in {R}enal {D}isease ({MDRD}) equation. {F}ollowing the {K}/{DOQI} recommendations, {CKD} was defined as e{GFR} <60ml/min/1.73m(2) at two consecutive measurements at least 3 months apart. {T}he factors associated with e{GFR} decline or {CKD} were identified by mixed linear regression and {C}ox regression, respectively.{R}esults{T}hree thousand, one hundred and thirty-eight patients (72% women) were followed for a median ({IQR}) of 4.5(2.2-6.9) years. {A}t baseline, median e{GFR} ({IQR}) was 110.7(94.4-128.4) ml/min/1.73m(2) and 93 (3%) patients exhibited e{GFR} <60ml/min/1.73m(2). {T}he lowest-performing progressions of e{GFR} during the first year of {ART} were observed in patients with 40-49yr. age range (-8.3[-11.7;-5.0] ml/min/1.73m(2), p<0.001), age50yr. (-6.2[-10.7;-1.8] ml/min/1.73m(2), p=0.006) and high blood pressure ({HBP}) (-28.4[-46.9;-9.9] ml/min/1.73m(2), p=0.003) at {ART} initiation. {R}egarding the {ART} exposure in patients with normal baseline e{GFR}, zidovudine ({AZT}) with protease inhibitor ({PI}) (-4.7[-7.7;-1.6] ml/min/1.73m(2), p=0.002), tenofovir ({TDF})+{PI} (-13.1[-17.4;-8.7] ml/min/1.73m(2), p<0.001), {TDF} without {PI} (-3.2[-5.0;-1.4] ml/min/1.73m(2), p<0.001), stavudine (d4{T})+{PI} (-8.5[-14.6-2.4] ml/min/1.73m(2), p=0.006) and d4{T} without {PI} (-5.0[-7.6-2.4] ml/min/1.73m(2), p<0.001) were associated with poorer e{GFR} progression. {T}he prevalence of {CKD} was 0.5% and the incidence was 1.9 [1.3; 2.7] cases/1000 person-years. {T}he risk of {CKD} was higher in patients with {HBP} (4.3[1.8;9.9], p=0.001), 40-49yr. patients (4.2[1.6;11.2], p=0.004), 50yr. patients (4.5[1.5;14.1], p=0.009) and patients exposed to abacavir ({ABC}) or didanosine (dd{I}) based {ART} (13.1[4.0;42.9], p<0.001).{C}onclusions{O}ur findings do not confirm the high risk of {CKD} reported in previous studies of {W}est {A}fricans with {HIV}, but support the recommendations for early initiation of {ART} and close kidney function monitoring in patients with {HBP} or aged 40yr.},
  keywords = {{CKD} ; {HIV} ; {A}ntiretroviral treatment ; {B}urkina {F}aso ; {A}frica ; {E}pidemiology ; {AFRIQUE} {DE} {L}'{OUEST} ; {BURKINA} {FASO}},
  booktitle = {},
  journal = {{BMC} {N}ephrology},
  volume = {20},
  numero = {},
  pages = {art. 155 [10 p.]},
  ISSN = {1471-2369},
  year = {2019},
  DOI = {10.1186/s12882-019-1335-9},
  URL = {https://www.documentation.ird.fr/hor/fdi:010075674},
}